Turkey : Pharmaceutical Sector Analysis
Pharmaceuticals are essential to achieve health outcomes, but are at the same time a major cost factor in every health system. From a patient perspective, access to pharmaceuticals is a proxy for the functioning of the health system. With increasin...
| Main Authors: | , |
|---|---|
| Format: | Report |
| Language: | English en_US |
| Published: |
Ankara, World Bank
2017
|
| Subjects: | |
| Online Access: | http://documents.worldbank.org/curated/en/389721468310466052/Turkey-Pharmaceutical-sector-analysis http://hdl.handle.net/10986/28110 |
| id |
okr-10986-28110 |
|---|---|
| recordtype |
oai_dc |
| spelling |
okr-10986-281102021-04-23T14:04:47Z Turkey : Pharmaceutical Sector Analysis Celik, Yusuf Seiter, Andreas ACCESS TO PHARMACEUTICALS AGGRESSIVE AGING ANTIBIOTICS BASIC HEALTH CARE BRAND BRAND LOYALTY BRAND NAME BRAND NAME DRUGS BRANDS BRIBERY BURDEN OF DISEASE CHEMISTS CHRONIC DISEASES CLINICAL BENEFIT CLINICAL PRACTICE CLINICAL TRIALS COMPETITIVENESS CONSUMER PROTECTION CONTROLLED SUBSTANCES CORRUPTION COST EFFECTIVENESS COST INCREASE COUNTERFEIT DRUGS CRIME DECISION MAKING DIAGNOSING DOCTORS DRUG ADMINISTRATION DRUG LAW DRUG PRICES EMPLOYMENT ESSENTIAL DRUGS EXPENDITURE EXPENDITURES FRAUD GENERIC DRUG COMPANIES GENERIC DRUGS GENERIC PRODUCTS GENERIC SUBSTITUTION GMP GOOD MANUFACTURING PRACTICES GREY MARKET GROSS DOMESTIC PRODUCT HEALTH CARE HEALTH CARE EXPENDITURES HEALTH CARE MANAGEMENT HEALTH CARE SERVICES HEALTH ECONOMICS HEALTH EXPENDITURE HEALTH EXPENDITURES HEALTH INSURANCE HEALTH INSURANCE COMPANIES HEALTH INSURERS HEALTH OUTCOMES HEALTH POLICY HEALTH SECTOR HEALTH SERVICES HEALTH STRATEGY HEALTH SYSTEM HEALTHCARE HEALTHCARE SERVICES HEROIN HOSPITALS ILL PEOPLE ILLNESS IMPORTED DRUGS INCOME INSURANCE COVERAGE INTEGRATION LAWS LEUKEMIA MARKET ACCESS MARKET ENTRY MARKET PRICE MARKET RESEARCH MARKET SHARE MARKETING MEDICAL SERVICES MEDICINE MEDICINES MINISTRIES OF HEALTH NARCOTICS NURSES NUTRITION OUTPATIENT SERVICES PACKAGING PATENTS PATIENT PATIENT EDUCATION PATIENTS PAYMENT TERMS PHARMACEUTICAL PHARMACEUTICAL CONSUMPTION PHARMACEUTICAL INDUSTRY PHARMACEUTICAL INSPECTION PHARMACEUTICAL MANUFACTURERS PHARMACEUTICAL MANUFACTURING PHARMACEUTICAL MARKETS PHARMACEUTICAL POLICY PHARMACEUTICAL PRICES PHARMACEUTICAL PRICING PHARMACEUTICAL PRODUCTS PHARMACEUTICAL SECTOR PHARMACEUTICALS PHARMACIES PHARMACISTS PHARMACOECONOMIC ANALYSIS PHARMACOECONOMIC STUDIES PHARMACOECONOMICS PHARMACOLOGISTS PHARMACOLOGY PHARMACY PHYSICIAN PHYSICIANS PRESCRIPTIONS PRICE ADJUSTMENTS PRICE CHANGES PRICE COMPARISON PRICE COMPETITION PRICE INCREASE PRICE LEVELS PRICE LIST PRIMARY CARE PRIVATE HEALTH INSURANCE PRIVATE PHARMACIES PROCUREMENT PSYCHOTROPIC DRUGS PUBLIC HEALTH PUBLIC HOSPITALS PURCHASING QUALITY OF CARE RATIONAL DRUG USE RATIONAL USE OF DRUGS REBATES REGULATORY AUTHORITIES RETAIL RETAIL PHARMACIES RETAIL PRICE RETAIL PRICES SALE SALES STOCKS SUBSTITUTE SUPPLY CHAIN SURGERY TENDERING THERAPIES TREATMENT GUIDELINES TREATMENTS VISITS WAREHOUSE WAREHOUSES WHOLESALER WHOLESALERS WORKERS Pharmaceuticals are essential to achieve health outcomes, but are at the same time a major cost factor in every health system. From a patient perspective, access to pharmaceuticals is a proxy for the functioning of the health system. With increasing economic strength, patients become more demanding with regard to access to modern, sophisticated drugs and providers become more aggressive in marketing those drugs. This paper reflects the situation in the pharmaceutical sector in Turkey, identifies critical issues, and discusses policy options based on current trends and the overall policy objectives of the Turkish government. This paper is structured as follows: chapter one gives introduction; chapter two gives overall policy objectives in the pharmaceutical sector in Turkey; chapter three presents institutional and regulatory framework; chapter four presents reimbursement rules; chapter five focuses on governance issues in the pharmaceutical sector; chapter six gives market overview; chapter seven gives payment for pharmaceuticals in Turkey; chapter eight presents prescribing practices - rational use of medicines; and chapter nine gives conclusions and way forward. 2017-09-05T21:43:03Z 2017-09-05T21:43:03Z 2008 Report http://documents.worldbank.org/curated/en/389721468310466052/Turkey-Pharmaceutical-sector-analysis http://hdl.handle.net/10986/28110 English en_US CC BY 3.0 IGO http://creativecommons.org/licenses/by/3.0/igo World Bank Ankara, World Bank Economic & Sector Work :: Other Health Study Economic & Sector Work Europe and Central Asia Turkey |
| repository_type |
Digital Repository |
| institution_category |
Foreign Institution |
| institution |
Digital Repositories |
| building |
World Bank Open Knowledge Repository |
| collection |
World Bank |
| language |
English en_US |
| topic |
ACCESS TO PHARMACEUTICALS AGGRESSIVE AGING ANTIBIOTICS BASIC HEALTH CARE BRAND BRAND LOYALTY BRAND NAME BRAND NAME DRUGS BRANDS BRIBERY BURDEN OF DISEASE CHEMISTS CHRONIC DISEASES CLINICAL BENEFIT CLINICAL PRACTICE CLINICAL TRIALS COMPETITIVENESS CONSUMER PROTECTION CONTROLLED SUBSTANCES CORRUPTION COST EFFECTIVENESS COST INCREASE COUNTERFEIT DRUGS CRIME DECISION MAKING DIAGNOSING DOCTORS DRUG ADMINISTRATION DRUG LAW DRUG PRICES EMPLOYMENT ESSENTIAL DRUGS EXPENDITURE EXPENDITURES FRAUD GENERIC DRUG COMPANIES GENERIC DRUGS GENERIC PRODUCTS GENERIC SUBSTITUTION GMP GOOD MANUFACTURING PRACTICES GREY MARKET GROSS DOMESTIC PRODUCT HEALTH CARE HEALTH CARE EXPENDITURES HEALTH CARE MANAGEMENT HEALTH CARE SERVICES HEALTH ECONOMICS HEALTH EXPENDITURE HEALTH EXPENDITURES HEALTH INSURANCE HEALTH INSURANCE COMPANIES HEALTH INSURERS HEALTH OUTCOMES HEALTH POLICY HEALTH SECTOR HEALTH SERVICES HEALTH STRATEGY HEALTH SYSTEM HEALTHCARE HEALTHCARE SERVICES HEROIN HOSPITALS ILL PEOPLE ILLNESS IMPORTED DRUGS INCOME INSURANCE COVERAGE INTEGRATION LAWS LEUKEMIA MARKET ACCESS MARKET ENTRY MARKET PRICE MARKET RESEARCH MARKET SHARE MARKETING MEDICAL SERVICES MEDICINE MEDICINES MINISTRIES OF HEALTH NARCOTICS NURSES NUTRITION OUTPATIENT SERVICES PACKAGING PATENTS PATIENT PATIENT EDUCATION PATIENTS PAYMENT TERMS PHARMACEUTICAL PHARMACEUTICAL CONSUMPTION PHARMACEUTICAL INDUSTRY PHARMACEUTICAL INSPECTION PHARMACEUTICAL MANUFACTURERS PHARMACEUTICAL MANUFACTURING PHARMACEUTICAL MARKETS PHARMACEUTICAL POLICY PHARMACEUTICAL PRICES PHARMACEUTICAL PRICING PHARMACEUTICAL PRODUCTS PHARMACEUTICAL SECTOR PHARMACEUTICALS PHARMACIES PHARMACISTS PHARMACOECONOMIC ANALYSIS PHARMACOECONOMIC STUDIES PHARMACOECONOMICS PHARMACOLOGISTS PHARMACOLOGY PHARMACY PHYSICIAN PHYSICIANS PRESCRIPTIONS PRICE ADJUSTMENTS PRICE CHANGES PRICE COMPARISON PRICE COMPETITION PRICE INCREASE PRICE LEVELS PRICE LIST PRIMARY CARE PRIVATE HEALTH INSURANCE PRIVATE PHARMACIES PROCUREMENT PSYCHOTROPIC DRUGS PUBLIC HEALTH PUBLIC HOSPITALS PURCHASING QUALITY OF CARE RATIONAL DRUG USE RATIONAL USE OF DRUGS REBATES REGULATORY AUTHORITIES RETAIL RETAIL PHARMACIES RETAIL PRICE RETAIL PRICES SALE SALES STOCKS SUBSTITUTE SUPPLY CHAIN SURGERY TENDERING THERAPIES TREATMENT GUIDELINES TREATMENTS VISITS WAREHOUSE WAREHOUSES WHOLESALER WHOLESALERS WORKERS |
| spellingShingle |
ACCESS TO PHARMACEUTICALS AGGRESSIVE AGING ANTIBIOTICS BASIC HEALTH CARE BRAND BRAND LOYALTY BRAND NAME BRAND NAME DRUGS BRANDS BRIBERY BURDEN OF DISEASE CHEMISTS CHRONIC DISEASES CLINICAL BENEFIT CLINICAL PRACTICE CLINICAL TRIALS COMPETITIVENESS CONSUMER PROTECTION CONTROLLED SUBSTANCES CORRUPTION COST EFFECTIVENESS COST INCREASE COUNTERFEIT DRUGS CRIME DECISION MAKING DIAGNOSING DOCTORS DRUG ADMINISTRATION DRUG LAW DRUG PRICES EMPLOYMENT ESSENTIAL DRUGS EXPENDITURE EXPENDITURES FRAUD GENERIC DRUG COMPANIES GENERIC DRUGS GENERIC PRODUCTS GENERIC SUBSTITUTION GMP GOOD MANUFACTURING PRACTICES GREY MARKET GROSS DOMESTIC PRODUCT HEALTH CARE HEALTH CARE EXPENDITURES HEALTH CARE MANAGEMENT HEALTH CARE SERVICES HEALTH ECONOMICS HEALTH EXPENDITURE HEALTH EXPENDITURES HEALTH INSURANCE HEALTH INSURANCE COMPANIES HEALTH INSURERS HEALTH OUTCOMES HEALTH POLICY HEALTH SECTOR HEALTH SERVICES HEALTH STRATEGY HEALTH SYSTEM HEALTHCARE HEALTHCARE SERVICES HEROIN HOSPITALS ILL PEOPLE ILLNESS IMPORTED DRUGS INCOME INSURANCE COVERAGE INTEGRATION LAWS LEUKEMIA MARKET ACCESS MARKET ENTRY MARKET PRICE MARKET RESEARCH MARKET SHARE MARKETING MEDICAL SERVICES MEDICINE MEDICINES MINISTRIES OF HEALTH NARCOTICS NURSES NUTRITION OUTPATIENT SERVICES PACKAGING PATENTS PATIENT PATIENT EDUCATION PATIENTS PAYMENT TERMS PHARMACEUTICAL PHARMACEUTICAL CONSUMPTION PHARMACEUTICAL INDUSTRY PHARMACEUTICAL INSPECTION PHARMACEUTICAL MANUFACTURERS PHARMACEUTICAL MANUFACTURING PHARMACEUTICAL MARKETS PHARMACEUTICAL POLICY PHARMACEUTICAL PRICES PHARMACEUTICAL PRICING PHARMACEUTICAL PRODUCTS PHARMACEUTICAL SECTOR PHARMACEUTICALS PHARMACIES PHARMACISTS PHARMACOECONOMIC ANALYSIS PHARMACOECONOMIC STUDIES PHARMACOECONOMICS PHARMACOLOGISTS PHARMACOLOGY PHARMACY PHYSICIAN PHYSICIANS PRESCRIPTIONS PRICE ADJUSTMENTS PRICE CHANGES PRICE COMPARISON PRICE COMPETITION PRICE INCREASE PRICE LEVELS PRICE LIST PRIMARY CARE PRIVATE HEALTH INSURANCE PRIVATE PHARMACIES PROCUREMENT PSYCHOTROPIC DRUGS PUBLIC HEALTH PUBLIC HOSPITALS PURCHASING QUALITY OF CARE RATIONAL DRUG USE RATIONAL USE OF DRUGS REBATES REGULATORY AUTHORITIES RETAIL RETAIL PHARMACIES RETAIL PRICE RETAIL PRICES SALE SALES STOCKS SUBSTITUTE SUPPLY CHAIN SURGERY TENDERING THERAPIES TREATMENT GUIDELINES TREATMENTS VISITS WAREHOUSE WAREHOUSES WHOLESALER WHOLESALERS WORKERS Celik, Yusuf Seiter, Andreas Turkey : Pharmaceutical Sector Analysis |
| geographic_facet |
Europe and Central Asia Turkey |
| description |
Pharmaceuticals are essential to achieve
health outcomes, but are at the same time a major cost
factor in every health system. From a patient perspective,
access to pharmaceuticals is a proxy for the functioning of
the health system. With increasing economic strength,
patients become more demanding with regard to access to
modern, sophisticated drugs and providers become more
aggressive in marketing those drugs. This paper reflects the
situation in the pharmaceutical sector in Turkey, identifies
critical issues, and discusses policy options based on
current trends and the overall policy objectives of the
Turkish government. This paper is structured as follows:
chapter one gives introduction; chapter two gives overall
policy objectives in the pharmaceutical sector in Turkey;
chapter three presents institutional and regulatory
framework; chapter four presents reimbursement rules;
chapter five focuses on governance issues in the
pharmaceutical sector; chapter six gives market overview;
chapter seven gives payment for pharmaceuticals in Turkey;
chapter eight presents prescribing practices - rational use
of medicines; and chapter nine gives conclusions and way forward. |
| format |
Report |
| author |
Celik, Yusuf Seiter, Andreas |
| author_facet |
Celik, Yusuf Seiter, Andreas |
| author_sort |
Celik, Yusuf |
| title |
Turkey : Pharmaceutical Sector Analysis |
| title_short |
Turkey : Pharmaceutical Sector Analysis |
| title_full |
Turkey : Pharmaceutical Sector Analysis |
| title_fullStr |
Turkey : Pharmaceutical Sector Analysis |
| title_full_unstemmed |
Turkey : Pharmaceutical Sector Analysis |
| title_sort |
turkey : pharmaceutical sector analysis |
| publisher |
Ankara, World Bank |
| publishDate |
2017 |
| url |
http://documents.worldbank.org/curated/en/389721468310466052/Turkey-Pharmaceutical-sector-analysis http://hdl.handle.net/10986/28110 |
| _version_ |
1764466299723841536 |